DUSA is a Wilmington, Mass-based dermatology company. Its commercial brands include BLU-U and LEVULAN/KERASTICK.
Levulan combination therapy is approved by FDA for treatment of non-hyperkeratotic actinic keratoses. BLU-U treatment has been approved by FDA for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions.
“We believe this transaction brings significant value to DUSA shareholders and are pleased that Sun Pharma recognized the value that has been created,” said Robert Doman, president and CEO of DUSA Pharmaceuticals, in the release. “We are confident that Sun Pharma will build upon the solid foundation our organization has established in the United States dermatology market to further expand access to Levulan for patients with actinic kerotoses.”
Sun Pharmaceutical Industries is headquartered in India.
Related Articles on Company Acquisitions:
Bausch + Lomb to Acquire Ophthalmology Laser Company
Sparton to Acquire Onyx EMS for $43M
Endeavour Capital Acquires Access Scientific
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
